Credit Suisse analyst Vamil Divan maintained a Hold rating on Eli Lilly & Co (NYSE: LLY) yesterday and set a price target of $84. The company’s shares closed yesterday at $89.71, close to its 52-week high of $89.87.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.3% and a 47.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Bristol Myers.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $92.83.
Based on Eli Lilly & Co’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.7 billion and net profit of $1.22 billion. In comparison, last year the company had a net profit of $1.01 billion.
Based on the recent corporate insider activity of 109 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health.